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Abstract: Balanced chromosomal translocations that generate chimeric oncoproteins are 
considered to be initiating lesions in the pathogenesis of acute myeloid leukemia. The most frequent 
is the t(15;17)(q22;q21), which fuses the 
leukemia (APL). An increasing proportion of APL cases are therapy
develop following exposure to radiotherapy and/or chemotherapeutic agents that target DNA 
topoisomerase II (topoII), particu
molecular mechanisms underlying the formation of the t(15;17) we mapped the translocation 
breakpoints in a series of t-APLs, which revealed significant clustering according 
the drug exposure. Remarkably, in approximately half of t
mitoxantrone treatment for breast 
within an 8-bp “hotspot” region in 
topoII-mediated DNA cleavage induced by mitoxantrone.
outside the “hotspot”, and the corresponding 
topoII cleavage sites. The observation that particular r
susceptible to topoII-mediated DNA damage induced by epirubicin and mitoxantrone may underlie 
the propensity of these agents to cause APL.
Introduction. Acute myeloid leukemia (AML) is 
characterized by a spectrum of recurring chromosomal 
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PML and RARA genes, giving rise to acute promyelocytic 
-related (t
larly mitoxantrone and epirubicin. To gain insights into 
-APL cases arising following 
cancer or multiple sclerosis, the chromosome 15 breakpoint fell 
PML intron 6, which was confirmed to be a pref
Chromosome 15 breakpoints falling 
RARA breakpoints were also shown to be functional 
egions of the PML 
abnormalities, which distinguish biologically and 
prognostically distinct subtypes of disease (reviewed 
.
5, F. Lo Coco2, N. 
th Floor, 
-mail:
-APL), which 
to the nature of 
erential site of 
and RARA loci are 
1). 
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To date, more than one hundred balanced chromosomal 
rearrangements (translocations, insertions and 
inversions) have been identified and cloned,2 with 
evidence suggesting that these are critical initiating 
events in the pathogenesis of AML. Identification of 
the genes involved in chromosomal rearrangements has 
provided major insights into the regulation of normal 
hematopoiesis and how disruption of key transcription 
factors and epigenetic modulators promote leukemic 
transformation. A number of genes, including MLL at 
11q23, NUP98 at 11p15, RARA at 17q21 and RUNX1 
at 21q22, are recurrent targets of chromosomal 
rearrangements in AML, being fused to a range of 
potential partner genes (reviewed 3). Interestingly, 
chromosomal rearrangements involving these 
particular loci also have been noted as a feature of 
secondary acute leukemias arising as a complication of 
prior therapy involving drugs targeting topoisomerase 
II (topoII), which are widely used in the treatment of a 
variety of tumors.4-13 TopoII is a critical enzyme that 
relaxes supercoiled DNA and removes knots and 
tangles from the genome by transiently cleaving and 
religating both strands of the double helix via the 
formation of a covalent cleavage intermediate
(reviewed 14). Epipodophyllotoxins (e.g. etoposide), 
anthracyclines (e.g. epirubicin) and anthracenediones 
(e.g. mitoxantrone) act as topoII poisons, inducing 
DNA damage by disrupting the cleavage-religation 
equilibrium and increasing the concentration of DNA 
topoII covalent complexes, which leads to apoptosis of 
the tumor cells.14
The association between exposure to 
chemotherapeutic agents targeting topoII and 
development of leukemias with balanced chromosomal 
rearrangements has naturally implicated the enzyme in 
this process, but the mechanisms involved have 
remained subject to debate. One hypothesis takes into 
account reports that leukemia-associated translocations 
can be detected in hematopoietic cells derived from 
healthy individuals without overt leukemia,15,16
suggesting that administration of chemotherapy and/or 
radiotherapy provides a selective advantage to 
progenitors with pre-existing translocations during 
regrowth of depopulated bone marrow. Moreover, the 
exposure to DNA damaging agents could lead to the 
acquisition of additional mutations that cooperate with 
the chimeric fusion protein generated by the 
translocation to induce leukemic transformation. A 
second hypothesis, based on findings with transformed 
cells, raised the possibility that agents targeting topoII 
could lead to the formation of chromosomal 
translocations through an indirect mechanism involving 
induction of apoptotic nucleases.17-20 Interestingly, Rolf 
Marschalek and colleagues provide evidence for a third 
potential mechanism, showing that the region of the 
MLL locus where breakpoints associated with infant 
and therapy-related leukemias cluster, colocalize with 
an internal promoter element, highlighting the 
relevance of chromatin structure and DNA topology in 
the genesis of chromosomal translocations.21 Finally, 
the fourth hypothesis, which is based on increasing 
biochemical and genetic evidence, suggests that in the 
presence of a topo II-targeting chemotherapeutic agent, 
topoII plays a direct role in generating double-stranded 
DNA breaks in regions of the genome that are 
particularly susceptible due to the nature of the 
surrounding chromatin. Following aberrant repair, 
these breaks go on to generate leukemia-associated 
chromosomal translocations (reviewed 22). 
Intriguingly, the nature of the drug exposure has a 
bearing on the molecular phenotype of the resultant 
secondary leukemia, with translocations involving the 
MLL gene at 11q23 being particularly associated with 
etoposide exposure.10,23,24 Development of therapy-
related acute promyelocytic leukemia (t-APL), 
characterized by the t(15;17)(q22;q21), has been linked 
to treatment with mitoxantrone and epirubicin.12,25,26
The t(15;17) leads to fusion of the gene encoding the 
myeloid transcription factor RAR (Retinoic Acid 
Receptor Alpha) at 17q21 with a gene that was 
previously unknown - designated PML (for 
ProMyelocytic Leukemia), which has subsequently 
been found to be involved in growth suppression and 
regulation of apoptosis (reviewed 27). This subtype of 
leukemia is of particular interest, being the first in 
which molecularly targeted therapies (i.e., all-
transretinoic acid [ATRA] and arsenic trioxide [ATO]) 
have been successfully used in clinical practice.27
These agents act by inducing degradation of the PML-
RAR oncoprotein, leading to clinical remission and 
have resulted in dramatic improvements in clinical 
outcome (reviewed 28). They also offer a potentially 
curative approach in patients with t-APL who have 
already received significant doses of chemotherapy for 
their previous condition and may be close to the 
anthracycline ceiling, or who are considered unfit for 
conventional therapy.29
The majority of t-APL cases arise in patients who 
have undergone treatment for breast cancer, where 
mitoxantrone and epirubicin have been widely 
used.12,25,26,30 In this setting, cumulative doses of 
epirubicin of ≤720mg/m2 have been associated with a 
secondary leukemia risk of 0.37% at 8 years.31 As more 
patients survive their primary cancers, secondary 
leukemias are becoming an increasing healthcare 
problem.32 Although t-APL remains relatively 
uncommon, two case series have suggested that the 
incidence has risen in recent years, with up to 20% of 
APL patients presenting with secondary disease.25,30
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Figure 1. Distribution of translocation breakpoints within the PML and RARA loci in t-APL cases arising following epirubicin and 
mitoxantrone. PML exons are represented by red boxes, RARA exons in blue and introns are represented by black lines. Arrows indicate the 
location of PML and RARA translocation breakpoints identified by long-range PCR and sequence analysis in patients with t-APL arising 
following mitoxantrone (red arrows) or epirubicin (green arrows). In 12 patients mitoxantrone was used for treatment of multiple sclerosis 
(MS). In the remaining 5 patients with mitoxantrone-related APL and the 6 patients with t-APL following epirubicin, these agents were used 
for prior breast cancer. Significant breakpoint clustering was observed, with a “hotspot” identified in PML intron 6 (position 1482-9) in 
mitoxantrone-related APL (following use of the drug for MS or breast cancer) and separate clusters associated with APL arising following 
epirubicin exposure. Chromosomal breakpoints were confirmed to be preferential sites of drug-induced topoisomerase II cleavage in 
functional assays (see Figure 2). Adapted from Mays et al.42 with permission.
Investigation of Molecular Mechanisms in 
Mitoxantrone-Related t-APL. As a first step to gain 
insights into mechanisms underlying formation of the 
t(15;17) we used long-range polymerase chain reaction 
(PCR) and sequence analysis to define chromosomal 
breakpoint locations, comparing the pattern between 
patients presenting de novo (n=35) and those with t-
APL occurring following exposure to mitoxantrone 
(n=6) or other agents/radiation therapy (n=7).33
Analysis of diagnostic samples from large cohorts of 
patients with de novo APL has established that the 
majority of chromosome 15 breakpoints fall within 3 
breakpoint cluster regions (bcr) i.e. in intron 3 (bcr3), 
intron 6 (bcr1) and exon 6 (bcr2) of the PML locus, 
accounting for approximately 40%, 55% and 5% of 
cases respectively.34 Chromosome 17 breakpoints fall 
within the ~17kb intron 2 of the RARA locus, such that 
the PML-RAR fusion retains key functional domains 
mediating DNA binding and interaction with 
coactivator/corepressors, retinoid-X-receptor and 
ligand (i.e. retinoic acid).27 While breakpoints observed 
in de novo APL appeared broadly distributed, 
chromosome 15 breakpoints of each of the 
mitoxantrone-related t-APLs fell within PML intron 6, 
with 4 cases clustering within an 8-bp region (position 
1482-9)(see Figure 1).33 Given that this intron is over 
1kb in length, this clustering of breakpoints was highly 
unlikely to have occurred by chance (p<0.001 by scan 
statistics). To investigate this further, we used a 
functional in vitro assay, in which substrates containing 
the normal homologues of the PML and RARA
translocation breakpoints are 5’-end-labelled and 
exposed to clinically relevant topoII poisons (e.g. 
mitoxantrone, epirubicin, etoposide) in the absence or 
presence of human topoII alpha; cleavage complexes 
are trapped and cleavage sites mapped in relation to the 
observed translocation breakpoints at the sequence 
level.35-37 These experiments demonstrated that the 
breakpoint “hotspot,” identified in t-APL patients 
previously treated with mitoxantrone for breast cancer, 
corresponded precisely to a preferential mitoxantrone-
induced topoII-dependent DNA cleavage site at 
position 1484 (see Figure 2).33 Moreover, each 
observed translocation breakpoint within the RARA
locus on chromosome 17 was confirmed to be a 
preferred site of topoII-mediated DNA damage induced 
by mitoxantrone (Figure 2).33
These data strongly implicated mitoxantrone in the
etiology of t-APL. However, it is important to consider
that the study of patients developing leukemia
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Figure 2. Demonstration of mitoxantrone-induced topoisomerase II dependent DNA cleavage at translocation breakpoints in therapy-related 
APL. A) In vitro DNA topoisomerase II (topoII) cleavage assay carried out for a PML substrate containing the breakpoints of 4 treatment-
related APL (t-APL) cases (F-8,-24,-25,-27) within the 8-bp breakpoint “hotspot” (positions 1482-1489). Patients received combination 
chemotherapy including the topoII poison mitoxantrone for breast cancer. Control reactions were carried out in the absence of topoII (lanes 
1-4), and in the presence of etoposide (VP16), etoposide catechol (VP16-OH), etoposide quinone (VP16-Q) and mitoxantrone (Mit).
Dideoxy sequencing reactions of the substrate are shown in lanes 5-8. Cleavage reactions were carried out by exposure to human topoII in 
the absence of drug (lane 9), and in the presence of etoposide (lane 10), etoposide catechol (lane 11), etoposide quinone (lane 12) and 
mitoxantrone (lane 13). Additional cleavage reactions were carried out to evaluate the heat-stability of cleavage complexes formed by 
incubation at 75C for 10 min (lanes 14-18). The nucleotide shown by the dash is the 5’side of the cleavage site (-1 position), which 
corresponds to the der(15) and der(17) translocation breakpoints in 4 cases of mitoxantrone-related APL (far right). The cleavage site at 
position 1484 was observed in the absence of drug, and in the presence of etoposide, both etoposide metabolites and mitoxantrone (lanes 9-
13). Cleavage at this position was the strongest site observed in the presence of mitoxantrone (lane 13). Furthermore, the complexes formed 
at this site were shown to be heat-stable in the presence of mitoxantrone (lane 18). Interestingly, a cleavage site at position 1502 is also 
observed, which corresponds to a breakpoint detected in a case of de novo APL.
B) TopoII cleavage assay of normal homologue of der(15) and der(17) RARA translocation breakpoints in APL of one of the mitoxantrone-
related cases (F-8). The substrate spanning positions 2603 to 2871 of RARA intron 2 contained the translocation breakpoints. Dash at right 
shows (-1) position of cleavage site corresponding to der(15) and der(17) translocation breakpoints (arrow far right). Adapted from Mistry et 
al.33 with permission.
following cancer therapy presents a challenge, given 
that they have often been exposed to multiple cytotoxic
drugs in addition to radiotherapy. This makes it 
difficult to identify the causative agent with any 
certainty. Moreover, such patient populations could 
feasibly be enriched for individuals at particular risk of 
leukemia, having already developed one form of 
cancer. Therefore, to provide further insights into 
molecular mechanisms in topoII-related leukemias, we 
analyzed a cohort of 12 patients collected from across 
Europe who developed APL following the use of single 
agent mitoxantrone to treat a benign condition, 
multiple sclerosis (MS), and in whom there was no 
history of previous cancer.38 Chromosome 15 
breakpoints again were found to cluster at position 
1484 within PML intron 6. Furthermore, shared 
chromosome 17 breakpoints that were preferential sites 
of mitoxantrone-induced topoII cleavage in functional 
assays were identified within RARAintron 2 (Figure 
1).38 The series of mitoxantrone-related t-APL cases 
analyzed has been further extended recently, with the 
chromosome 15 breakpoint found to fall within the 
“hotspot” region in 12 of 23 cases (52%).33,38,39
Comparison of the genomic breakpoint junction 
regions with the native genes showed that 
translocations in mitoxantrone-related t-APL were 
reciprocal, generally without loss or gain of 
nucleotides.33,38 Presence of sequence homologies 
between PML and RARA suggests that topoII-mediated 
DNA damage may be repaired by the canonical 
nonhomologous end-joining (NHEJ) or the alternative 
end-joining (alt-NHEJ) pathway, which require 
minimal overlapping sequences between 
nonhomologous chromosomes to repair double-
stranded DNA breaks (reviewed40). Using the 
information derived from genomic breakpoint junction 
sequence analysis and in vitro cleavage assays, the 
knowledge that topoII introduces staggered nicks in
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Figure 3. Model for formation of the t(15;17) in a case of mitoxantrone-related t-APL (case F8) following topoII induced cleavage in PML
and RARA loci with 4-base 5’ overhangs and aberrant DNA repair. Native PML and RARA sequences are red and blue, respectively. The 
processing includes exonucleolytic nibbling to form two-base (der(15)) or single-base (der(17)) homologies and creation of both breakpoint 
junctions by error-prone nonhomologous end-joining (NHEJ). In formation of the der(15), positions 1487-1488 on the antisense strand of 
PML are lost by exonucleolytic nibbling (pink) before NHEJ joins the indicated bases. Positions 1485-1487 on the sense strand of PML are 
lost by exonucleolytic nibbling (pink) and the der(17) forms by NHEJ. Template-directed polymerization of the relevant single-stranded 
overhangs fills in any gaps (light blue). Each RARA overhang is preserved completely. Adapted from Mistry et al.33 with permission.
DNA with 4-bp overhangs22 and considering known 
mechanisms of DNA repair it was possible to construct 
models by which the t(15;17) may have been formed in 
each case analyzed (see Figures 3 & 4). Taken 
together, these data provide very strong evidence that 
mitoxantrone is a causative agent in the pathogenesis 
of t-APL.
Investigation of Molecular Mechanisms in t-APL
Cases Arising Following Other TopoII Poisons. 
Epirubicin exposure has been linked to secondary 
leukemias with a range of balanced rearrangements, 
including translocations involving the MLL locus, core 
binding factor leukemias and t-APL with the 
t(15;17).31,41 In order to gain further insights into 
molecular mechanisms underlying epirubicin-related 
leukemias, we characterized t(15;17) genomic 
breakpoint junction regions in a series of 6 t-APL cases 
that arose following breast cancer therapy.42 Epirubicin 
was generally used as a component of combination 
chemotherapy, with a median latency period from first 
exposure to presentation of t-APL of 26 months (range 
18-48 months). Although the number of cases 
examined was small, significant breakpoint clustering 
was observed in both the PML and RARA loci (P= .009 
and P = .017, respectively), with PML breakpoints 
lying outside the mitoxantrone-associated “hotspot” 
region (Figure 1). Functional assays demonstrated that 
recurrent breakpoints identified in the PML and RARA
loci in epirubicin-related t-APL were preferential sites 
of topoII-induced DNA damage that were enhanced by 
epirubicin.42 Again, using the same approach as for 
mitoxantrone-related t-APLs, models could be 
constructed to explain the formation of the t(15;17) in 
APLs arising following epirubicin exposure.42
There also have been reports of t-APL occurring 
following treatment with other topoII poisons (e.g., 
etoposide) used for lymphomas and various solid 
tumors, as well as Langerhans cell histiocytosis.12,25,43
To determine whether topoII–mediated cleavage is 
relevant to other drugs associated with t-APL, we also 
have studied a patient in whom APL developed after 
treatment for laryngeal carcinoma that included 
etoposide and doxorubicin.33 Etoposide and its
metabolites and doxorubicin induced topoII to cleave
DNA at the PML and RARA translocation breakpoints. 
Moreover, the cleavage sites could recombine to form
the der(15) and der(17) breakpoint junctions observed 
in this patient. Taken together, these results suggest 
that topoII–mediated cleavage is a general mechanism
causing DNA damage in APL that develops after 
treatment with various agents that target topoII (Figure
Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 4. Model summarizing formation of reciprocal translocation breakpoint junctions in treatment related APL directly by generation of 
drug-stimulated topoisomerase II cleavage complexes and near-precise or precise NHEJ repair. Adapted from Felix et al.22 with permission.
4).
Concluding Remarks. While therapy-related 
leukemias are still relatively uncommon, they are 
characterized by the same range of cytogenetic 
abnormalities that are found in cases of AML arising 
de novo.44,45 Indeed, greater understanding of therapy-
related leukemias may provide significant insights into 
the biology of their de novo counterparts. For example, 
defining the latency period between first exposure to a 
leukemogenic agent (e.g. mitoxantrone) and 
presentation with full blown leukemia, provides clues 
to the timeframe between acquisition of chromosomal 
rearrangements such as the t(15;17) and progression to 
leukemia in the de novo setting. Analysis of t-APL 
cases suggests that the median time to develop APL 
from the formation of the t(15;17) is ~27 months,33,38,42
implying the need for cooperating mutations. While 
logistically challenging, therapy-related leukemias 
afford the opportunity for tracking the stepwise 
acquisition of mutations that are required for 
progression to full-blown leukemia,46,47 and which may 
be of relevance to the pathogenesis of leukemias 
arising de novo. While we have observed a few cases 
of t-APL that present within 12 months from first 
mitoxantrone exposure, latency periods in the majority 
of cases are much longer. This may account for why, 
even if the t(15;17) were acquired in some cases in 
utero, de novo pediatric APL only very rarely presents 
in infancy.  
A number of studies conducted over the last three 
decades have served to identify specific dosing 
schedules or particular agents that are associated with 
high rates of induction of secondary leukemias,32,48-51
leading to the development of effective alternative 
treatment protocols that are substantially safer.52-54
However, the study of patients with t-APL has 
demonstrated that therapy-related leukemias also can 
occur in patients subject to very low level exposure, as 
exemplified by a case of APL involving the PML
breakpoint “hotspot” arising following a single 15 mg 
dose of mitoxantrone used as adjuvant chemotherapy 
for breast cancer.33 Epidemiology studies conducted in 
MS patients treated with mitoxantrone have suggested 
that the risk of development of secondary leukemia is 
~1 in 370, 55,56 with the majority of reported cases being 
t-APL. This raises key questions as to the extent to 
which the play of chance is involved in the 
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development of therapy-related leukemias, as well as 
the relative importance of patient predisposition to the 
development of this complication. A number of 
prerequisites have to be satisfied to develop leukemia 
following treatment with a topoII poison. Firstly, 
double-strand DNA breaks must occur within two 
genes with the potential to form oncogenic fusions. 
These breaks then need to be repaired to generate in-
frame functional chimeric fusion genes. This 
translocation event needs to occur in a progenitor 
permissive for leukemic transformation and finally the 
necessary cooperating mutations are acquired. While 
our studies have provided evidence that topoII plays a 
direct role in mediating DNA damage that leads to 
formation of the t(15;17) in t-APL, a key question 
remains as to whether the enzyme is also involved in 
the formation of chromosomal translocations in de 
novo leukemias. Exposure to environmental toxins and 
agents targeting topoII has been implicated in the 
development of infant leukemia with translocations 
involving MLL at 11q23.57-59 Interestingly, recent 
evidence lends further support for topoII in the etiology 
of chromosomal translocations, inducing DNA damage 
in the TMPRSS2 and ERG loci in response to androgen 
signalling, leading to formation of fusion genes 
involved in prostate cancer.60
It is readily conceivable that genetic susceptibility 
to primary tumors due to mutations or functional 
variants for example in DNA repair pathways also 
could increase the risk of development of secondary 
leukemias. Interestingly, a recent genome-wide 
association study has implicated variants in the 
PRDM1 gene at 6q21 in the development of second 
neoplasms in children treated with radiotherapy for 
Hodgkin’s disease,61 whereas whole genome 
sequencing applied in a case of therapy-related AML 
arising from early-onset BRCA1/2 mutation-negative 
breast and ovarian cancer revealed a novel TP53 cancer 
susceptibility mutation.62 The spectrum of resultant 
leukemias could reflect the nature of the genetic 
susceptibility as well as the agents preferentially used 
for the particular primary condition, as would be 
suggested by the propensity of etoposide to induce 
secondary leukemias involving the MLL gene at 11q23 
and epirubicin and mitoxantrone to induce t-APL. 
Moreover, genetic variation in the handling of a range 
of specific cytotoxic agents could affect an individual’s 
risk of developing secondary leukemia (reviewed 63). 
Indeed, it has recently been reported that genetic 
variants of genes encoding drug-metabolizing enzymes 
and components of DNA repair pathways are 
associated with increased susceptibility to development 
of t-APL in patients with MS receiving mitoxantrone.64
Dissecting out the relative importance of these 
factors represents a considerable challenge. It requires 
the analysis of substantial patient cohorts, which are 
well characterized both in terms of their primary 
tumors, prior cytotoxic therapy and cytogenetic and 
molecular profile of the secondary leukemias. 
Nevertheless, significant progress in this research area 
is likely to be fruitful allowing not only the 
development of more individualized and safer 
approaches to treatment of primary tumors, but also 
(potentially) providing insights into molecular 
mechanisms underlying the pathogenesis of de novo
leukemias. Thus, it could afford improved 
understanding of AML as a whole. 
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